Investor Briefing with Steven Yatomi-Clarke

In this session Prescient CEO and Managing Director Steven Yatomi-Clarke discussed the key highlights:

  • The new PTX-100 Phase 1b clinical study results, following their unveiling at the American Society of Hematology (ASH) conference.
  • The next steps for PTX-100 including preparation for a meeting with the FDA to discuss using the Phase 2 trial as a registrational study.
  • The potential significance of accelerating approval and commercialisation of PTX-100 in an orphan disease.

Recorded on 18th December 2023 at 12pm (AEDT).

Join the next Prescient webcast

Featured Speaker

Steven Yatomi-Clarke

CEO and Managing DirectorPrescient Therapeutics (ASX: PTX)

Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.

 

Reach Corporate provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.

Any advice contained within this presentation is general advice and does not consider your personal circumstances, you should consider whether it is appropriate for you. The information we are giving you is for educational purposes only. “Investing is about understanding your risk” and every time you invest in the share market there is a risk of loss.

Past performance is not a reliable indicator of future performance.

This update is being hosted by Reach Markets Pty Ltd (CAR of AFSL 333297) and Reach does not assume responsibility for the accuracy or completeness of any information provided, and any communication from Reach has been prepared with all reasonable care and may be based on unverified information obtained from sources believed to be reliable. However, except to the extent required by law, Reach including its representatives, employees, agents or contractors are not liable to you for any loss or damage resulting directly or indirectly from access to information and do not accept any responsibility for errors and omissions, nor make any warranty or representation as to the reliability, suitability, confidentiality, accuracy, completeness or timeliness of information as it may change without notice and so Reach has no obligation to keep the information current.

Forward Looking Statements relate to intentions, future acts and events that are only predictions and are subject to risks, uncertainties and assumptions, which are outside the control of Reach. These may include commodity prices, currency fluctuations, economic and financial market conditions in various countries and regions, environmental risks and legislative, fiscal or regulatory developments, political risks, project delay or advancement, approvals and cost estimates. Actual values, results or events may be materially different to those expressed or implied and given these uncertainties, readers are cautioned not to place reliance on Forward Looking Statements. Information and views from third parties may be produced solely for convenience and are not endorsed nor reflective of Reach’s position.

latest other webcasts

Prescient Therapeutics (ASX: PTX) Webcast Replay

Felix Gold (ASX: FXG) Webcast Replay

Prescient Therapeutics (ASX: PTX) Q&A Investor Update